<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340037</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>02</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Beta Spike-Presenting SARS-CoV-2 Virus-like Particle Vaccine Confers Broad Protection against Other VOCs in Mice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1007</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091007</ELocationID><Abstract><AbstractText>Virus-like particles (VLPs) are non-infectious and serve as promising vaccine platforms because they mimic the membrane-embedded conformations of fusion glycoproteins on native viruses. Here, we employed SARS-CoV-2 VLPs (SMEN) presenting ancestral, Beta, or Omicron spikes to identify the variant spike that elicits potent and cross-protective immune responses in the highly sensitive K18-hACE2 challenge mouse model. A combined intranasal and intramuscular SMEN vaccine regimen generated the most effective immune responses to significantly reduce disease burden. Protection was primarily mediated by antibodies, with minor but distinct contributions from T cells in reducing virus spread and inflammation. Immunization with SMEN carrying ancestral spike resulted in 100, 75, or 0% protection against ancestral, Delta, or Beta variant-induced mortality, respectively. However, SMEN with an Omicron spike provided only limited protection against ancestral (50%), Delta (0%), and Beta (25%) challenges. By contrast, SMEN with Beta spikes offered 100% protection against the variants used in this study. Thus, the Beta variant not only overcame the immunity produced by other variants, but the Beta spike also elicited diverse and effective humoral immune responses. Our findings suggest that leveraging the Beta variant spike protein can enhance SARS-CoV-2 immunity, potentially leading to a more comprehensive vaccine against emerging variants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ullah</LastName><ForeName>Irfan</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-7760-8693</Identifier><AffiliationInfo><Affiliation>Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Symmes</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keita</LastName><ForeName>Kadiatou</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grunst</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><Identifier Source="ORCID">0000-0002-8575-8026</Identifier><AffiliationInfo><Affiliation>Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wenwei</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-3008-6901</Identifier><AffiliationInfo><Affiliation>Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mothes</LastName><ForeName>Walther</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Priti</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uchil</LastName><ForeName>Pradeep D</ForeName><Initials>PD</Initials><Identifier Source="ORCID">0000-0002-7236-858X</Identifier><AffiliationInfo><Affiliation>Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 AI055403</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>487578</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>F31 AI176650</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24 OD026440</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R24TW026440-03S1</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>177958</GrantID><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>R01 AI163395</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01AI163395-03A1</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Beta</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cross-VOC protection</Keyword><Keyword MajorTopicYN="N">intramuscular</Keyword><Keyword MajorTopicYN="N">intranasal</Keyword><Keyword MajorTopicYN="N">neutralizing antibodies</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword><Keyword MajorTopicYN="N">variants of concern</Keyword><Keyword MajorTopicYN="N">virus-like particles</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340037</ArticleId><ArticleId IdType="pmc">PMC11435481</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091007</ArticleId><ArticleId IdType="pii">vaccines12091007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A., Li F. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581:221–224. doi: 10.1038/s41586-020-2179-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2179-y</ArticleId><ArticleId IdType="pmc">PMC7328981</ArticleId><ArticleId IdType="pubmed">32225175</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23:3–20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O., Graham B.S., McLellan J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263. doi: 10.1126/science.abb2507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb2507</ArticleId><ArticleId IdType="pmc">PMC7164637</ArticleId><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181:281–292.e6. doi: 10.1016/j.cell.2020.02.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.058</ArticleId><ArticleId IdType="pmc">PMC7102599</ArticleId><ArticleId IdType="pubmed">32155444</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Zhang Y., Wu L., Niu S., Song C., Zhang Z., Lu G., Qiao C., Hu Y., Yuen K.Y., et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell. 2020;181:894–904.e9. doi: 10.1016/j.cell.2020.03.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.03.045</ArticleId><ArticleId IdType="pmc">PMC7144619</ArticleId><ArticleId IdType="pubmed">32275855</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi R., Shan C., Duan X., Chen Z., Liu P., Song J., Song T., Bi X., Han C., Wu L., et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584:120–124. doi: 10.1038/s41586-020-2381-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2381-y</ArticleId><ArticleId IdType="pubmed">32454512</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomerie I., Bird T.W., Palmer O.R., Mason N.C., Pankhurst T.E., Lawley B., Hernández L.C., Harfoot R., Authier-Hall A., Anderson D.E., et al. Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants. iScience. 2023;26:106256. doi: 10.1016/j.isci.2023.106256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2023.106256</ArticleId><ArticleId IdType="pmc">PMC9940465</ArticleId><ArticleId IdType="pubmed">36845030</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari M., Su S.-C., Liang K.-H., Lin H.-T., Lu Y.-F., Chen K.-C., Chen W.-Y., Wu H.-C. Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern. J. Biomed. Sci. 2023;30:46. doi: 10.1186/s12929-023-00936-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-023-00936-0</ArticleId><ArticleId IdType="pmc">PMC10304269</ArticleId><ArticleId IdType="pubmed">37380988</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer Zu Natrup C., Tscherne A., Dahlke C., Ciurkiewicz M., Shin D.L., Fathi A., Rohde C., Kalodimou G., Halwe S., Limpinsel L., et al. Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity. J. Clin. Investig. 2022;132:e159895. doi: 10.1172/JCI159895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI159895</ArticleId><ArticleId IdType="pmc">PMC9754005</ArticleId><ArticleId IdType="pubmed">36301637</ArticleId></ArticleIdList></Reference><Reference><Citation>Ao D., Lan T., He X., Liu J., Chen L., Baptista-Hon D.T., Zhang K., Wei X. SARS-CoV-2 Omicron variant: Immune escape and vaccine development. MedComm. 2022;3:e126. doi: 10.1002/mco2.126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.126</ArticleId><ArticleId IdType="pmc">PMC8925644</ArticleId><ArticleId IdType="pubmed">35317190</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau J.J., Cheng S.M.S., Leung K., Lee C.K., Hachim A., Tsang L.C.H., Yam K.W.H., Chaothai S., Kwan K.K.H., Chai Z.Y.H., et al. Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. Nat. Med. 2023;29:348–357. doi: 10.1038/s41591-023-02219-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02219-5</ArticleId><ArticleId IdType="pmc">PMC9941049</ArticleId><ArticleId IdType="pubmed">36652990</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohsin M., Mahmud S., Uddin Mian A., Hasan P., Muyeed A., Taif Ali M., Faysal Ahmed F., Islam A., Maliha Rahman M., Islam M., et al. Side effects of COVID-19 vaccines and perceptions about COVID-19 and its vaccines in Bangladesh: A Cross-sectional study. Vaccine X. 2022;12:100207. doi: 10.1016/j.jvacx.2022.100207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvacx.2022.100207</ArticleId><ArticleId IdType="pmc">PMC9394094</ArticleId><ArticleId IdType="pubmed">36032698</ArticleId></ArticleIdList></Reference><Reference><Citation>Schäfer I., Oltrogge J.H., Nestoriuc Y., Warren C.V., Brassen S., Blattner M., Lühmann D., Tinnermann A., Scherer M., Büchel C. Expectations and Prior Experiences Associated With Adverse Effects of COVID-19 Vaccination. JAMA Netw. Open. 2023;6:e234732. doi: 10.1001/jamanetworkopen.2023.4732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.4732</ArticleId><ArticleId IdType="pmc">PMC10043751</ArticleId><ArticleId IdType="pubmed">36972051</ArticleId></ArticleIdList></Reference><Reference><Citation>Solís Arce J.S., Warren S.S., Meriggi N.F., Scacco A., McMurry N., Voors M., Syunyaev G., Malik A.A., Aboutajdine S., Adeojo O., et al. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nat. Med. 2021;27:1385–1394. doi: 10.1038/s41591-021-01454-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01454-y</ArticleId><ArticleId IdType="pmc">PMC8363502</ArticleId><ArticleId IdType="pubmed">34272499</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkurt B., Kamat I., Hotez P.J. Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2021;144:471–484. doi: 10.1161/CIRCULATIONAHA.121.056135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.056135</ArticleId><ArticleId IdType="pmc">PMC8340726</ArticleId><ArticleId IdType="pubmed">34281357</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekal S., Husari G., Okura M., Huang C.A., Bukari M.S. Thrombosis Development After mRNA COVID-19 Vaccine Administration: A Case Series. Cureus. 2023;15:e41371. doi: 10.7759/cureus.41371.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.41371</ArticleId><ArticleId IdType="pmc">PMC10400017</ArticleId><ArticleId IdType="pubmed">37546104</ArticleId></ArticleIdList></Reference><Reference><Citation>SeyedAlinaghi S., Karimi A., Pashaei Z., Afzalian A., Mirzapour P., Ghorbanzadeh K., Ghasemzadeh A., Dashti M., Nazarian N., Vahedi F., et al. Safety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review. Arch. Acad. Emerg. Med. 2022;10:e41. doi: 10.22037/aaem.v10i1.1597.</Citation><ArticleIdList><ArticleId IdType="doi">10.22037/aaem.v10i1.1597</ArticleId><ArticleId IdType="pmc">PMC9206826</ArticleId><ArticleId IdType="pubmed">35765616</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosseini R., Askari N. A review of neurological side effects of COVID-19 vaccination. Eur. J. Med. Res. 2023;28:102. doi: 10.1186/s40001-023-00992-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-023-00992-0</ArticleId><ArticleId IdType="pmc">PMC9959958</ArticleId><ArticleId IdType="pubmed">36841774</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J.J., Schonborn L., Warkentin T.E., Chataway T., Grosse L., Simioni P., Moll S., Greinacher A., Gordon T.P. Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders. N. Engl. J. Med. 2024;390:1827–1829. doi: 10.1056/NEJMc2402592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2402592</ArticleId><ArticleId IdType="pubmed">38749041</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu K.B., Quan F.S. Respiratory Viruses and Virus-like Particle Vaccine Development: How Far Have We Advanced? Viruses. 2023;15:392. doi: 10.3390/v15020392.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15020392</ArticleId><ArticleId IdType="pmc">PMC9965150</ArticleId><ArticleId IdType="pubmed">36851606</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X., Xia Y., Liu X., Xu Y., Lu P., Dong Z., Liu J., Liang G. A perspective on SARS-CoV-2 virus-like particles vaccines. Int. Immunopharmacol. 2023;115:109650. doi: 10.1016/j.intimp.2022.109650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2022.109650</ArticleId><ArticleId IdType="pmc">PMC9832101</ArticleId><ArticleId IdType="pubmed">36649673</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz I.C., Ipekoglu E.M., Bulbul A., Turay N., Yildirim M., Evcili I., Yilmaz N.S., Guvencli N., Aydin Y., Gungor B., et al. Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection. Allergy. 2022;77:258–270. doi: 10.1111/all.15091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.15091</ArticleId><ArticleId IdType="pmc">PMC8653174</ArticleId><ArticleId IdType="pubmed">34519053</ArticleId></ArticleIdList></Reference><Reference><Citation>Naskalska A., Dabrowska A., Szczepanski A., Jasik K.P., Gromadzka B., Pyrc K. Functional Severe Acute Respiratory Syndrome Coronavirus 2 Virus-Like Particles From Insect Cells. Front. Microbiol. 2021;12:732998. doi: 10.3389/fmicb.2021.732998.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.732998</ArticleId><ArticleId IdType="pmc">PMC8565087</ArticleId><ArticleId IdType="pubmed">34745036</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq H., Batool S., Asif S., Ali M., Abbasi B.H. Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases. Front. Microbiol. 2021;12:790121. doi: 10.3389/fmicb.2021.790121.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.790121</ArticleId><ArticleId IdType="pmc">PMC8761975</ArticleId><ArticleId IdType="pubmed">35046918</ArticleId></ArticleIdList></Reference><Reference><Citation>Nooraei S., Bahrulolum H., Hoseini Z.S., Katalani C., Hajizade A., Easton A.J., Ahmadian G. Virus-like particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J. Nanobiotechnol. 2021;19:59. doi: 10.1186/s12951-021-00806-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12951-021-00806-7</ArticleId><ArticleId IdType="pmc">PMC7905985</ArticleId><ArticleId IdType="pubmed">33632278</ArticleId></ArticleIdList></Reference><Reference><Citation>Comas-Garcia M., Colunga-Saucedo M., Rosales-Mendoza S. The Role of Virus-Like Particles in Medical Biotechnology. Mol. Pharm. 2020;17:4407–4420. doi: 10.1021/acs.molpharmaceut.0c00828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.0c00828</ArticleId><ArticleId IdType="pubmed">33147978</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed A.M., Taha T.Y., Tabata T., Chen I.P., Ciling A., Khalid M.M., Sreekumar B., Chen P.Y., Hayashi J.M., Soczek K.M., et al. Rapid assessment of SARS-CoV-2-evolved variants using virus-like particles. Science. 2021;374:1626–1632. doi: 10.1126/science.abl6184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abl6184</ArticleId><ArticleId IdType="pmc">PMC9005165</ArticleId><ArticleId IdType="pubmed">34735219</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C.W., Valkenburg S.A., Poon L.L.M., Wang L.F. Broad-spectrum pan-genus and pan-family virus vaccines. Cell Host Microbe. 2023;31:902–916. doi: 10.1016/j.chom.2023.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2023.05.017</ArticleId><ArticleId IdType="pmc">PMC10265776</ArticleId><ArticleId IdType="pubmed">37321173</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu M. Single-Molecule FRET Imaging of Virus Spike-Host Interactions. Viruses. 2021;13:332. doi: 10.3390/v13020332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13020332</ArticleId><ArticleId IdType="pmc">PMC7924862</ArticleId><ArticleId IdType="pubmed">33669922</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey W.T., Carabelli A.M., Jackson B., Gupta R.K., Thomson E.C., Harrison E.M., Ludden C., Reeve R., Rambaut A., Peacock S.J., et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 2021;19:409–424. doi: 10.1038/s41579-021-00573-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00573-0</ArticleId><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov P.V., Ghafari M., Beer M., Lythgoe K., Simmonds P., Stilianakis N.I., Katzourakis A. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 2023;21:361–379. doi: 10.1038/s41579-023-00878-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Liu Q., Zhou L., Zhou Y., Yan H., Lan K. Emerging SARS-CoV-2 variants: Why, how, and what’s next? Cell Insight. 2022;1:100029. doi: 10.1016/j.cellin.2022.100029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellin.2022.100029</ArticleId><ArticleId IdType="pmc">PMC9057926</ArticleId><ArticleId IdType="pubmed">37193049</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldblatt D., Alter G., Crotty S., Plotkin S.A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol. Rev. 2022;310:6–26. doi: 10.1111/imr.13091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.13091</ArticleId><ArticleId IdType="pmc">PMC9348242</ArticleId><ArticleId IdType="pubmed">35661178</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullah I., Escudie F., Scandale I., Gilani Z., Gendron-Lepage G., Gaudette F., Mowbray C., Fraisse L., Bazin R., Finzi A., et al. Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens. iScience. 2024;27:109049. doi: 10.1016/j.isci.2024.109049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2024.109049</ArticleId><ArticleId IdType="pmc">PMC10867665</ArticleId><ArticleId IdType="pubmed">38361624</ArticleId></ArticleIdList></Reference><Reference><Citation>Torii S., Ono C., Suzuki R., Morioka Y., Anzai I., Fauzyah Y., Maeda Y., Kamitani W., Fukuhara T., Matsuura Y. Establishment of a reverse genetics system for SARS-CoV-2 using circular polymerase extension reaction. Cell Rep. 2021;35:109014. doi: 10.1016/j.celrep.2021.109014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109014</ArticleId><ArticleId IdType="pmc">PMC8015404</ArticleId><ArticleId IdType="pubmed">33838744</ArticleId></ArticleIdList></Reference><Reference><Citation>Amarilla A.A., Sng J.D.J., Parry R., Deerain J.M., Potter J.R., Setoh Y.X., Rawle D.J., Le T.T., Modhiran N., Wang X., et al. A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses. Nat. Commun. 2021;12:3431. doi: 10.1038/s41467-021-23779-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23779-5</ArticleId><ArticleId IdType="pmc">PMC8187723</ArticleId><ArticleId IdType="pubmed">34103499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullah I., Prevost J., Ladinsky M.S., Stone H., Lu M., Anand S.P., Beaudoin-Bussieres G., Symmes K., Benlarbi M., Ding S., et al. Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity. 2021;54:2143–2158 e2115. doi: 10.1016/j.immuni.2021.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.08.015</ArticleId><ArticleId IdType="pmc">PMC8372518</ArticleId><ArticleId IdType="pubmed">34453881</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullah I., Beaudoin-Bussieres G., Symmes K., Cloutier M., Ducas E., Tauzin A., Laumaea A., Grunst M.W., Dionne K., Richard J., et al. The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. Cell Rep. Med. 2023;4:100893. doi: 10.1016/j.xcrm.2022.100893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100893</ArticleId><ArticleId IdType="pmc">PMC9799175</ArticleId><ArticleId IdType="pubmed">36584683</ArticleId></ArticleIdList></Reference><Reference><Citation>Papini C., Ullah I., Ranjan A.P., Zhang S., Wu Q., Spasov K.A., Zhang C., Mothes W., Crawford J.M., Lindenbach B.D., et al. Proof-of-concept studies with a computationally designed M(pro) inhibitor as a synergistic combination regimen alternative to Paxlovid. Proc. Natl. Acad. Sci. USA. 2024;121:e2320713121. doi: 10.1073/pnas.2320713121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2320713121</ArticleId><ArticleId IdType="pmc">PMC11046628</ArticleId><ArticleId IdType="pubmed">38621119</ArticleId></ArticleIdList></Reference><Reference><Citation>Grandi A., Tomasi M., Ullah I., Bertelli C., Vanzo T., Accordini S., Gagliardi A., Zanella I., Benedet M., Corbellari R., et al. Immunogenicity and Pre-Clinical Efficacy of an OMV-Based SARS-CoV-2 Vaccine. Vaccines. 2023;11:1546. doi: 10.3390/vaccines11101546.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11101546</ArticleId><ArticleId IdType="pmc">PMC10610814</ArticleId><ArticleId IdType="pubmed">37896949</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianevski A., Giri A.K., Aittokallio T. SynergyFinder 2.0: Visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48:W488–W493. doi: 10.1093/nar/gkaa216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa216</ArticleId><ArticleId IdType="pmc">PMC7319457</ArticleId><ArticleId IdType="pubmed">32246720</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastronarde D.N. Automated electron microscope tomography using robust prediction of specimen movements. J. Struct. Biol. 2005;152:36–51. doi: 10.1016/j.jsb.2005.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2005.07.007</ArticleId><ArticleId IdType="pubmed">16182563</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagen W.J.H., Wan W., Briggs J.A.G. Implementation of a cryo-electron tomography tilt-scheme optimized for high resolution subtomogram averaging. J. Struct. Biol. 2017;197:191–198. doi: 10.1016/j.jsb.2016.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2016.06.007</ArticleId><ArticleId IdType="pmc">PMC5287356</ArticleId><ArticleId IdType="pubmed">27313000</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastronarde D.N., Held S.R. Automated tilt series alignment and tomographic reconstruction in IMOD. J. Struct. Biol. 2017;197:102–113. doi: 10.1016/j.jsb.2016.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsb.2016.07.011</ArticleId><ArticleId IdType="pmc">PMC5247408</ArticleId><ArticleId IdType="pubmed">27444392</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng S.Q., Palovcak E., Armache J.P., Verba K.A., Cheng Y., Agard D.A. MotionCor2: Anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods. 2017;14:331–332. doi: 10.1038/nmeth.4193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.4193</ArticleId><ArticleId IdType="pmc">PMC5494038</ArticleId><ArticleId IdType="pubmed">28250466</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherwood E.R., Burelbach K.R., McBride M.A., Stothers C.L., Owen A.M., Hernandez A., Patil N.K., Williams D.L., Bohannon J.K. Innate Immune Memory and the Host Response to Infection. J. Immunol. 2022;208:785–792. doi: 10.4049/jimmunol.2101058.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2101058</ArticleId><ArticleId IdType="pmc">PMC8982914</ArticleId><ArticleId IdType="pubmed">35115374</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajishengallis G., Netea M.G., Chavakis T. Innate immune memory, trained immunity and nomenclature clarification. Nat. Immunol. 2023;24:1393–1394. doi: 10.1038/s41590-023-01595-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01595-x</ArticleId><ArticleId IdType="pubmed">37620602</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaughan A.E., Brumwell A.N., Xi Y., Gotts J.E., Brownfield D.G., Treutlein B., Tan K., Tan V., Liu F.C., Looney M.R., et al. Lineage-negative progenitors mobilize to regenerate lung epithelium after major injury. Nature. 2015;517:621–625. doi: 10.1038/nature14112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14112</ArticleId><ArticleId IdType="pmc">PMC4312207</ArticleId><ArticleId IdType="pubmed">25533958</ArticleId></ArticleIdList></Reference><Reference><Citation>Strunz M., Simon L.M., Ansari M., Kathiriya J.J., Angelidis I., Mayr C.H., Tsidiridis G., Lange M., Mattner L.F., Yee M., et al. Alveolar regeneration through a Krt8+ transitional stem cell state that persists in human lung fibrosis. Nat. Commun. 2020;11:3559. doi: 10.1038/s41467-020-17358-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17358-3</ArticleId><ArticleId IdType="pmc">PMC7366678</ArticleId><ArticleId IdType="pubmed">32678092</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray S., Chiba N., Yao C., Guan X., McConnell A.M., Brockway B., Que L., McQualter J.L., Stripp B.R. Rare SOX2(+) Airway Progenitor Cells Generate KRT5(+) Cells that Repopulate Damaged Alveolar Parenchyma following Influenza Virus Infection. Stem Cell Rep. 2016;7:817–825. doi: 10.1016/j.stemcr.2016.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2016.09.010</ArticleId><ArticleId IdType="pmc">PMC5106521</ArticleId><ArticleId IdType="pubmed">27773701</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar P.A., Hu Y., Yamamoto Y., Hoe N.B., Wei T.S., Mu D., Sun Y., Joo L.S., Dagher R., Zielonka E.M., et al. Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection. Cell. 2011;147:525–538. doi: 10.1016/j.cell.2011.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.10.001</ArticleId><ArticleId IdType="pmc">PMC4040224</ArticleId><ArticleId IdType="pubmed">22036562</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J., Park J.E., Tsagkogeorga G., Yanagita M., Koo B.K., Han N., Lee J.H. Inflammatory Signals Induce AT2 Cell-Derived Damage-Associated Transient Progenitors that Mediate Alveolar Regeneration. Cell Stem Cell. 2020;27:366–382 e367. doi: 10.1016/j.stem.2020.06.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2020.06.020</ArticleId><ArticleId IdType="pmc">PMC7487779</ArticleId><ArticleId IdType="pubmed">32750316</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd D.F., Allen E.K., Randolph A.G., Guo X.J., Weng Y., Sanders C.J., Bajracharya R., Lee N.K., Guy C.S., Vogel P., et al. Exuberant fibroblast activity compromises lung function via ADAMTS4. Nature. 2020;587:466–471. doi: 10.1038/s41586-020-2877-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2877-5</ArticleId><ArticleId IdType="pmc">PMC7883627</ArticleId><ArticleId IdType="pubmed">33116313</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K.K., Tsung-Ning Huang D., Huang L.M. SARS-CoV-2 variants-Evolution, spike protein, and vaccines. Biomed. J. 2022;45:573–579. doi: 10.1016/j.bj.2022.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bj.2022.04.006</ArticleId><ArticleId IdType="pmc">PMC9072773</ArticleId><ArticleId IdType="pubmed">35526825</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannar D., Saville J.W., Zhu X., Srivastava S.S., Berezuk A.M., Tuttle K.S., Marquez A.C., Sekirov I., Subramaniam S. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex. Science. 2022;375:760–764. doi: 10.1126/science.abn7760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn7760</ArticleId><ArticleId IdType="pmc">PMC9799367</ArticleId><ArticleId IdType="pubmed">35050643</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing M., Hu G., Wang X., Wang Y., He F., Dai W., Wang X., Niu Y., Liu J., Liu H., et al. An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza. NPJ Vaccines. 2024;9:64. doi: 10.1038/s41541-024-00857-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-024-00857-5</ArticleId><ArticleId IdType="pmc">PMC10954707</ArticleId><ArticleId IdType="pubmed">38509167</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh J.E., Song E., Moriyama M., Wong P., Zhang S., Jiang R., Strohmeier S., Kleinstein S.H., Krammer F., Iwasaki A. Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA. Sci. Immunol. 2021;6:eabj5129. doi: 10.1126/sciimmunol.abj5129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abj5129</ArticleId><ArticleId IdType="pmc">PMC8762609</ArticleId><ArticleId IdType="pubmed">34890255</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao T., Israelow B., Pena-Hernandez M.A., Suberi A., Zhou L., Luyten S., Reschke M., Dong H., Homer R.J., Saltzman W.M., et al. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science. 2022;378:eabo2523. doi: 10.1126/science.abo2523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abo2523</ArticleId><ArticleId IdType="pmc">PMC9798903</ArticleId><ArticleId IdType="pubmed">36302057</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki A. Exploiting Mucosal Immunity for Antiviral Vaccines. Annu. Rev. Immunol. 2016;34:575–608. doi: 10.1146/annurev-immunol-032414-112315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-032414-112315</ArticleId><ArticleId IdType="pubmed">27168245</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert P.B., Montefiori D.C., McDermott A.B., Fong Y., Benkeser D., Deng W., Zhou H., Houchens C.R., Martins K., Jayashankar L., et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375:43–50. doi: 10.1126/science.abm3425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm3425</ArticleId><ArticleId IdType="pmc">PMC9017870</ArticleId><ArticleId IdType="pubmed">34812653</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran W.F., Lam E.C., Astudillo M.G., Yang D., Miller T.E., Feldman J., Hauser B.M., Caradonna T.M., Clayton K.L., Nitido A.D., et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021;184:476–488 e411. doi: 10.1016/j.cell.2020.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.015</ArticleId><ArticleId IdType="pmc">PMC7837114</ArticleId><ArticleId IdType="pubmed">33412089</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Munoz A.D., Kosik I., Holly J., Yewdell J.W. Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive immunity. Sci. Adv. 2022;8:eabp9770. doi: 10.1126/sciadv.abp9770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abp9770</ArticleId><ArticleId IdType="pmc">PMC9348789</ArticleId><ArticleId IdType="pubmed">35921414</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Munoz A.D., Santos J.J.S., Yewdell J.W. Cell surface nucleocapsid protein expression: A betacoronavirus immunomodulatory strategy. Proc. Natl. Acad. Sci. USA. 2023;120:e2304087120. doi: 10.1073/pnas.2304087120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2304087120</ArticleId><ArticleId IdType="pmc">PMC10334784</ArticleId><ArticleId IdType="pubmed">37399385</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M., Karki R., Williams E.P., Yang D., Fitzpatrick E., Vogel P., Jonsson C.B., Kanneganti T.D. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat. Immunol. 2021;22:829–838. doi: 10.1038/s41590-021-00937-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-00937-x</ArticleId><ArticleId IdType="pmc">PMC8882317</ArticleId><ArticleId IdType="pubmed">33963333</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrozek-Latecka M., Kozlowski P., Hoser G., Bandyszewska M., Hanusek K., Nowis D., Golab J., Grzanka M., Piekielko-Witkowska A., Schulz L., et al. SARS-CoV-2 and its ORF3a, E and M viroporins activate inflammasome in human macrophages and induce of IL-1alpha in pulmonary epithelial and endothelial cells. Cell Death Discov. 2024;10:191. doi: 10.1038/s41420-024-01966-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-024-01966-9</ArticleId><ArticleId IdType="pmc">PMC11045860</ArticleId><ArticleId IdType="pubmed">38664396</ArticleId></ArticleIdList></Reference><Reference><Citation>Helft J., Manicassamy B., Guermonprez P., Hashimoto D., Silvin A., Agudo J., Brown B.D., Schmolke M., Miller J.C., Leboeuf M., et al. Cross-presenting CD103+ dendritic cells are protected from influenza virus infection. J. Clin. Investig. 2012;122:4037–4047. doi: 10.1172/JCI60659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI60659</ArticleId><ArticleId IdType="pmc">PMC3484433</ArticleId><ArticleId IdType="pubmed">23041628</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinkernagel R.M. On cross-priming of MHC class I-specific CTL: Rule or exception? Eur. J. Immunol. 2002;32:2385–2392. doi: 10.1002/1521-4141(200209)32:9&lt;2385::AID-IMMU2385&gt;3.0.CO;2-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1521-4141(200209)32:9&lt;2385::AID-IMMU2385&gt;3.0.CO;2-V</ArticleId><ArticleId IdType="pubmed">12207322</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein S.R., Ramelli S.C., Grazioli A., Chung J.Y., Singh M., Yinda C.K., Winkler C.W., Sun J., Dickey J.M., Ylaya K., et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612:758–763. doi: 10.1038/s41586-022-05542-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohandas S., Jagannathan P., Henrich T.J., Sherif Z.A., Bime C., Quinlan E., Portman M.A., Gennaro M., Rehman J., Force R.M.P.T. Immune mechanisms underlying COVID-19 pathology and post-acute sequelae of SARS-CoV-2 infection (PASC) eLife. 2023;12:e86014. doi: 10.7554/eLife.86014.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.86014</ArticleId><ArticleId IdType="pmc">PMC10219649</ArticleId><ArticleId IdType="pubmed">37233729</ArticleId></ArticleIdList></Reference><Reference><Citation>Mourad A., Thibault D., Holland T.L., Yang S., Young A.R., Arnold Egloff S.A., Thomas L.E. Dexamethasone for Inpatients With COVID-19 in a National Cohort. JAMA Netw. Open. 2023;6:e238516. doi: 10.1001/jamanetworkopen.2023.8516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.8516</ArticleId><ArticleId IdType="pmc">PMC10111178</ArticleId><ArticleId IdType="pubmed">37067800</ArticleId></ArticleIdList></Reference><Reference><Citation>Wibmer C.K., Ayres F., Hermanus T., Madzivhandila M., Kgagudi P., Oosthuysen B., Lambson B.E., de Oliveira T., Vermeulen M., van der Berg K., et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat. Med. 2021;27:622–625. doi: 10.1038/s41591-021-01285-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01285-x</ArticleId><ArticleId IdType="pubmed">33654292</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S.I., Manamela N.P., Motsoeneng B.M., Kaldine H., Ayres F., Makhado Z., Mennen M., Skelem S., Williams N., Sullivan N.J., et al. SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity. Cell Rep. Med. 2022;3:100510. doi: 10.1016/j.xcrm.2022.100510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100510</ArticleId><ArticleId IdType="pmc">PMC8761540</ArticleId><ArticleId IdType="pubmed">35233544</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham B.S., Gilman M.S.A., McLellan J.S. Structure-Based Vaccine Antigen Design. Annu. Rev. Med. 2019;70:91–104. doi: 10.1146/annurev-med-121217-094234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-121217-094234</ArticleId><ArticleId IdType="pmc">PMC6936610</ArticleId><ArticleId IdType="pubmed">30691364</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders R.W., Moore J.P. Virus vaccines: Proteins prefer prolines. Cell Host Microbe. 2021;29:327–333. doi: 10.1016/j.chom.2021.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.02.002</ArticleId><ArticleId IdType="pmc">PMC7945883</ArticleId><ArticleId IdType="pubmed">33705704</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne P.O., McLellan J.S. Principles and practical applications of structure-based vaccine design. Curr. Opin. Immunol. 2022;77:102209. doi: 10.1016/j.coi.2022.102209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2022.102209</ArticleId><ArticleId IdType="pmc">PMC9611442</ArticleId><ArticleId IdType="pubmed">35598506</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh C.L., Goldsmith J.A., Schaub J.M., DiVenere A.M., Kuo H.C., Javanmardi K., Le K.C., Wrapp D., Lee A.G., Liu Y., et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. 2020;369:1501–1505. doi: 10.1126/science.abd0826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd0826</ArticleId><ArticleId IdType="pmc">PMC7402631</ArticleId><ArticleId IdType="pubmed">32703906</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu M., Ma X., Castillo-Menendez L.R., Gorman J., Alsahafi N., Ermel U., Terry D.S., Chambers M., Peng D., Zhang B., et al. Associating HIV-1 envelope glycoprotein structures with states on the virus observed by smFRET. Nature. 2019;568:415–419. doi: 10.1038/s41586-019-1101-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1101-y</ArticleId><ArticleId IdType="pmc">PMC6655592</ArticleId><ArticleId IdType="pubmed">30971821</ArticleId></ArticleIdList></Reference><Reference><Citation>Sponholtz M.R., Byrne P.O., Lee A.G., Ramamohan A.R., Goldsmith J.A., McCool R.S., Zhou L., Johnson N.V., Hsieh C.-L., Connors M., et al. Structure-based design of a soluble human cytomegalovirus glycoprotein B antigen stabilized in a prefusion-like conformation. bioRxiv. 2024 doi: 10.1101/2024.02.10.579772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.02.10.579772</ArticleId><ArticleId IdType="pmc">PMC11406251</ArticleId><ArticleId IdType="pubmed">39231203</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>